Table 3.
Outcomes of primary (n=4) and post-chemotherapy (n=23) RPLND.
| pRPLND (N=4) | pcRPLND (N=23) | |
|---|---|---|
| Positive nodes at RPLND1, median (IQR) | 1 (1, 4) | 0 (0, 1) |
| Nodes removed at RPLND1 (N=22), median (IQR) | 58 (37, 71) | 38 (18, 48) |
| N stage at RPLND, n (%) | ||
| pN1 | 0 | 3 (13) |
| pN2 | 4 (100) | 1 (4.3) |
| pN3 | 0 | 2 (8.7) |
| pN0 | 0 | 17 (74) |
| Pathologic size of largest node at RPLND (N=9), cm median (IQR) | 2.8 (2.5, 3.7) | 1.0 (0.9, 4.0) |
| Histology at RPLND, n {%) | ||
| Benign or fibrosis/necrosis | 0 | 17 (74) |
| Teratoma, only | 0 | 3 (13) |
| Viable tumor | 4 (100) | 3 (13) |
| Choriocarcinoma | 0 | 1 (33) |
| Pure seminoma | 4 (100%) | 1 (33) |
| Teratoma with secondary somatic type malignancy | 0 | 1 (33) |
1
Number of nodes removed and their positivity status available for 22 patients only.
RPLND: retroperitoneal lymph node dissection; pRPLND: primary RPLND; pcRPLND: post-chemotherapy RPLND.